로딩 중…
지수 로딩 중…
KYUNG NAM PHARM.CO.,LTD.
053950· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩1,651-1.43%
2026-11-02
Financials
Valuation Metrics
KYUNG NAM PHARM.CO.,LTD.'s Market Cap is ₩324B. At end of 2025 it was ₩665B. Ranked #1986 of 2,405 in KR market (top 83%), #1251 of 1,627 on KOSDAQ (top 77%), #211 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 91%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 32.39B KRW | KR#1,986/2,405 Sec#211/231 |
| Revenue | 62.76B KRW | KR#1,670/2,405 Sec#111/231 |
| Net Income | -14.23B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 143.23B KRW | KR#1,541/2,405 Sec#118/231 |
| Net Assets | 117.50B KRW | KR#1,302/2,405 Sec#102/231 |
| Employees | 260 | KR#897/2,405 Sec#75/231 |
| Value | ||
| P/B | 0.28x | KR#329/2,405 Sec#12/231 |
| P/S | 0.52x | KR#996/2,405 Sec#49/231 |
| FCF Yield | -9.06% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -12.11% | KR#1,971/2,405 Sec#149/231 |
| ROA | -9.94% | KR#2,093/2,405 Sec#158/231 |
| Op. Margin | -1.33% | KR#1,700/2,405 Sec#115/231 |
| Revenue Growth | 14.33% | KR#711/2,405 Sec#70/231 |
| Financial Health | ||
| Debt Ratio | 21.90% | KR#410/2,405 Sec#51/231 |
| Total Debt | 5.16B KRW | KR#1,766/2,405 Sec#168/231 |
| FCF | -2.93B KRW | KR#1,380/2,405 Sec#108/231 |
| Cash | 18.40B KRW | KR#1,294/2,405 Sec#98/231 |
| Current Ratio | 2.77x | KR#606/2,405 Sec#80/231 |
| Performance | ||
| 1Y Return | -58.20% | KR#2,061/2,405 Sec#184/231 |
| 1M Return | -17.28% | KR#1,711/2,405 Sec#167/231 |
| From 52W High | -70.41% | KR#2,064/2,405 Sec#171/231 |
| 1Y MDD | -70.26% | KR#1,962/2,405 Sec#167/231 |
| Trading | ||
| Volume | 71,667 shares | KR#778/2,405 Sec#82/231 |
| Trading Value | 117.0M KRW | KR#1,375/2,405 Sec#150/231 |
| Foreign Own. | 0.00% | KR—/2,405 Sec—/231 |
| Per Share | ||
| EPS | -725 KRW | KR—/2,405 Sec—/231 |
| BPS | 5,989 KRW | KR#1,371/2,405 Sec#97/231 |
Company Info
Kyungnam Pharm, established in 1998 and listed on KOSDAQ in 2001, adopted its current name after merging with HS Biopharm in 2010. The company manufactures and sells pharmaceuticals and health functional foods, distributing flagship products like Lemona nationwide through pharmacies and large supermarkets. It is expanding its business beyond its OTC specialist image, diversifying and growing the Lemona product line to increase sales and customer engagement through enhanced online marketing.